Hana Pharm Co., Ltd. (KRX:293480)

Hana Pharm Statistics

Total Valuation

Hana Pharm has a market cap or net worth of KRW 201.01 billion.

Market Cap	201.01B
Enterprise Value	n/a

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Hana Pharm has 17.77 million shares outstanding.

Current Share Class	17.77M
Shares Outstanding	17.77M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	57.71%
Owned by Institutions (%)	0.47%
Float	7.10M

Valuation Ratios

The trailing PE ratio is 5.04.

PE Ratio	5.04
Forward PE	n/a
PS Ratio	1.44
PB Ratio	2.47
P/TBV Ratio	2.59
P/FCF Ratio	13.24
P/OCF Ratio	7.92
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.36.

Current Ratio	1.63
Quick Ratio	1.22
Debt / Equity	0.36
Debt / EBITDA	0.82
Debt / FCF	1.91
Interest Coverage	30.47

Financial Efficiency

Return on equity (ROE) is 35.53% and return on invested capital (ROIC) is 20.21%.

Return on Equity (ROE)	35.53%
Return on Assets (ROA)	15.52%
Return on Invested Capital (ROIC)	20.21%
Return on Capital Employed (ROCE)	34.27%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	1.09
Inventory Turnover	2.43

Taxes

In the past 12 months, Hana Pharm has paid 6.66 billion in taxes.

Income Tax	6.66B
Effective Tax Rate	21.51%

Stock Price Statistics

The stock price has decreased by -0.88% in the last 52 weeks. The beta is 0.34, so Hana Pharm's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	-0.88%
50-Day Moving Average	11,823.40
200-Day Moving Average	11,418.25
Relative Strength Index (RSI)	27.80
Average Volume (20 Days)	28,151

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hana Pharm had revenue of KRW 139.33 billion and earned 24.30 billion in profits. Earnings per share was 2,243.00.

Revenue	139.33B
Gross Profit	94.00B
Operating Income	31.81B
Pretax Income	30.96B
Net Income	24.30B
EBITDA	35.33B
EBIT	31.81B
Earnings Per Share (EPS)	2,243.00

Balance Sheet

The company has 16.49 billion in cash and 29.05 billion in debt, giving a net cash position of -12.56 billion or -706.42 per share.

Cash & Cash Equivalents	16.49B
Total Debt	29.05B
Net Cash	-12.56B
Net Cash Per Share	-706.42
Equity (Book Value)	81.30B
Book Value Per Share	7,469.67
Working Capital	30.69B

Cash Flow

In the last 12 months, operating cash flow was 25.38 billion and capital expenditures -10.19 billion, giving a free cash flow of 15.19 billion.

Operating Cash Flow	25.38B
Capital Expenditures	-10.19B
Free Cash Flow	15.19B
FCF Per Share	854.50

Margins

Gross margin is 67.47%, with operating and profit margins of 22.83% and 17.44%.

Gross Margin	67.47%
Operating Margin	22.83%
Pretax Margin	22.22%
Profit Margin	17.44%
EBITDA Margin	25.36%
EBIT Margin	22.83%
FCF Margin	10.90%

Dividends & Yields

This stock pays an annual dividend of 510.00, which amounts to a dividend yield of 4.52%.

Dividend Per Share	510.00
Dividend Yield	4.52%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	4.21%
Buyback Yield	n/a
Shareholder Yield	4.43%
Earnings Yield	12.09%
FCF Yield	7.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on April 28, 2021. It was a forward split with a ratio of 1.1000011.

Last Split Date	Apr 28, 2021
Split Type	Forward
Split Ratio	1.1000011

Scores

Hana Pharm has an Altman Z-Score of 2.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	4